Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23,359.93% | 23,340.07% | 5.90% | 4.86% | -3.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23,359.93% | 23,340.07% | 5.90% | 4.86% | -3.82% |
| Cost of Revenue | 33.02% | 46.90% | 77.14% | 154.70% | 64.79% |
| Gross Profit | 1.57% | -5.59% | -77.29% | -155.24% | -64.96% |
| SG&A Expenses | 56.04% | -1.61% | -20.81% | -28.38% | -35.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.24% | 40.79% | 48.12% | 41.63% | 17.50% |
| Operating Income | -22.69% | -15.93% | -48.17% | -41.67% | -17.52% |
| Income Before Tax | -26.91% | -17.46% | -50.87% | -41.35% | -13.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.91% | -17.46% | -50.87% | -41.35% | -13.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.91% | -17.46% | -50.87% | -41.35% | -13.55% |
| EBIT | -22.69% | -15.93% | -48.17% | -41.67% | -17.52% |
| EBITDA | -22.76% | -15.99% | -48.31% | -41.79% | -17.55% |
| EPS Basic | -7.62% | -29.53% | -40.24% | -9.67% | 24.75% |
| Normalized Basic EPS | -1.91% | 13.77% | -4.80% | 5.95% | 25.56% |
| EPS Diluted | -7.62% | -29.53% | -40.24% | -9.67% | 24.75% |
| Normalized Diluted EPS | -1.91% | 13.77% | -4.80% | 5.95% | 25.56% |
| Average Basic Shares Outstanding | 24.93% | 34.73% | 41.74% | 47.54% | 51.78% |
| Average Diluted Shares Outstanding | 24.93% | 34.73% | 41.74% | 47.54% | 51.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |